. Author manuscript; available in PMC: 2022 Oct 14.

Published in final edited form as: FASEB J. 2022 Oct;36(10):e22514. doi: 10.1096/fj.202200765R

Table 1:

Clinical samples used in this study.

Code	Gender	Age	Dis Stage	AML Subtype	WBC (10e3/uL)	% Blasts	Molecular	Cytogenetics
1103	F	41	Dx	De Novo	247.25	86%	FLT3-ITD, NOTCH1, PTPN11	46,XX
1172	F	46	Dx	De Novo	149.23	96%	FLT3-ITD	46,XX
1241	F	50	Dx	De Novo	180.4	90%	NPM1, FLT3-ITD	46,XX
1099	M	86	Dx	De Novo	141.02	61%	N/A	46,XY
934	F	72	Dx	De Novo	137.78	98%	NPM1, FLT3-ITD	46,XX
1071	M	81	Dx	De Novo	148.89	98%	N/A	47, XY,+8[18]